Literature DB >> 24409209

Optimizing care and outcomes of patients with muscle-invasive bladder cancer.

Christopher M Booth1.   

Abstract

Entities:  

Year:  2013        PMID： 24409209      PMCID： PMC3886198          DOI： 10.5489/cuaj.1698

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  26 in total

Review 1.  Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

Authors:  David D Chism; Michael E Woods; Matthew I Milowsky
Journal:  Oncologist       Date:  2013-07-24

2.  Evaluating the quality of medical care. 1966.

Authors:  Avedis Donabedian
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

3.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Authors: 
Journal:  Eur Urol       Date:  2005-04-25       Impact factor: 20.096

4.  Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.

Authors:  Jo-An Seah; Normand Blais; Scott North; Yasmin Rahim; Dean Ruether; Peter C Black; Alexandre R Zlotta; Lori Wood; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

Review 5.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Authors:  Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-03-23       Impact factor: 20.096

6.  Use of radical cystectomy for patients with invasive bladder cancer.

Authors:  John L Gore; Mark S Litwin; Julie Lai; Elizabeth M Yano; Rodger Madison; Claude Setodji; John L Adams; Christopher S Saigal
Journal:  J Natl Cancer Inst       Date:  2010-04-16       Impact factor: 13.506

7.  Information needs of men regarding prostate cancer screening and the effect of a brief decision aid.

Authors:  Stacey L Sheridan; Kathryn Felix; Michael P Pignone; Carmen L Lewis
Journal:  Patient Educ Couns       Date:  2004-09

Review 8.  Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

Authors:  Cora N Sternberg; S Machele Donat; Joaquim Bellmunt; Randall E Millikan; Walter Stadler; Pieter De Mulder; Amir Sherif; Hans von der Maase; Taiji Tsukamoto; Mark S Soloway
Journal:  Urology       Date:  2007-01       Impact factor: 2.649

9.  Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer.

Authors:  Michael P Porter; Matthew C Kerrigan; Bonnie M K Donato; Scott D Ramsey
Journal:  Urol Oncol       Date:  2009-05-17       Impact factor: 3.498

10.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Authors:  Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544
View more
  1 in total

1.  Survival after radiotherapy versus radical cystectomy for primary muscle-invasive bladder cancer: A Swedish nationwide population-based cohort study.

Authors:  Christel Häggström; Hans Garmo; Xavier de Luna; Mieke Van Hemelrijck; Karin Söderkvist; Firas Aljabery; Viveka Ströck; Abolfazl Hosseini; Truls Gårdmark; Per-Uno Malmström; Staffan Jahnson; Fredrik Liedberg; Lars Holmberg
Journal:  Cancer Med       Date:  2019-04-01       Impact factor: 4.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.